Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.

Published in: Vaccines (2022)

This article reviews the literature on SARS-CoV-2 pandemic and multiple sclerosis (MS). The first part of the paper focuses on the current data on immunopathology of SARS-CoV-2 and leading vaccines produced against COVID-19 infection. In the second part of the article, we discuss the effect of Disease Modifying Therapies (DMTs) on COVID-19 infection severity or SARS-CoV-2 vaccination in MS patients plus safety profile of different vaccine platforms in MS patients.

Keyphrases

sars cov
multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
respiratory syndrome coronavirus
mass spectrometry
coronavirus disease
systematic review
ms ms
inflammatory response
big data